Erschienen in:
01.01.2013 | Adis Drug Clinical Q&A
Once-Daily Memantine
A Guide to its Use in Moderate to Severe Alzheimer’s Disease in the EU
verfasst von:
Katherine A. Lyseng-Williamson, Kate McKeage
Erschienen in:
Drugs & Aging
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Abstract
In the EU, once-daily memantine 20 mg (Axura®, Ebixa®) is an option for the management of patients with moderate to severe Alzheimer’s disease (AD). In pooled clinical trials and studies in the clinical practice setting, memantine 20 mg/day improved cognition, functional ability and behavioural symptoms in this patient population. The beneficial effects of memantine are associated with delays in the need for full-time care, which were predicted to result in cost savings relative to standard care in recent cost-utility analyses in patients with moderate to severe AD conducted in EU countries. Memantine is well tolerated, with an adverse event profile that is similar to that with placebo.